Dr. Wade A. Brosius, DO
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Philadelphia College of Osteopathic Medicine (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 340
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: Philadelphia College of Osteopathic Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
PA license OS008179L
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Paoli Hospital Paoli, PA
- Phoenixville Hospital Phoenixville, PA
- Pottstown Hospital Pottstown, PA
Medical groups
- Pottstown Medical Specialists Inc (40 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 340
- Services billed
- 2,375
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 372 | 51 |
| Established patient office or other outpatient visit, 30-39 minutes | 272 | 170 |
| Annual depression screening, 5 to 15 minutes | 141 | 141 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 135 | 135 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 65 | 28 |
| Advance care planning, first 30 minutes | 60 | 60 |
| Administration of influenza virus vaccine | 52 | 52 |
| Influenza vaccine split virus, preservative free | 51 | 50 |
| Established patient office or other outpatient visit, 20-29 minutes | 37 | 37 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 29 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 52 payments worth $1,137 in total to this clinician.
| Lilly USA, LLC | $121 |
|---|---|
| Sanofi Pasteur Inc. | $117 |
| Novartis Pharmaceuticals Corporation | $116 |
| Abbott Laboratories | $115 |
| Novo Nordisk Inc | $103 |
| AbbVie Inc. | $91.06 |
| GlaxoSmithKline, LLC. | $75.16 |
| Pfizer Inc. | $63.88 |
| Food and Beverage | $1,137 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $73,766 in research payments for these studies, mostly to the institutions running them.
- A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
Amgen Inc. - Roche Cancer Screening Collection Study
Genentech, Inc. - A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease an…
AstraZeneca Pharmaceuticals LP - Informed Choice Intervention for Colorectal Cancer Screening: COMPASS
Exact Sciences Corporation - Informed Choice - Compass
Exact Sciences Corporation · Terminated · NCT05246839
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.